Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. Quality of life (QOL) scores for functional scale items

Published byGregory Willis Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2. Quality of life (QOL) scores for functional scale items"— Presentation transcript:

1 Figure 2. Quality of life (QOL) scores for functional scale items
Figure 2. Quality of life (QOL) scores for functional scale items. **P value <0.05 (using paired T test). From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10): doi: /annonc/mdq749 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

2 Figure 1. Overview of the clinical trial.
From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10): doi: /annonc/mdq749 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

3 Figure 3. Quality of life (QOL) scores for symptom scales items
Figure 3. Quality of life (QOL) scores for symptom scales items. **P value <0.05 (using paired T test), ##P value <0.05 (using T test). From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10): doi: /annonc/mdq749 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

4 Figure 4. Immune cells in study and control group. #P value <0
Figure 4. Immune cells in study and control group. #P value <0.05 (using Wilcoxon signed- ranks test). *P value <0.05 (using Mann–Whitney test). From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10): doi: /annonc/mdq749 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

5 Figure 5. Cytokine-secreting cells (ELISPOTS/10<sup>^</sup>6 peripheral blood mononuclear) in study and control groups. #P value <0.05 (using Wilcoxon signed- ranks test). *P value <0.05 (using Mann–Whitney test). From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10): doi: /annonc/mdq749 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

Download ppt "Figure 2. Quality of life (QOL) scores for functional scale items"

Similar presentations

From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Fig. 1 Graphical representation

Fig. 1 Graphical representation
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
From: Political Leadership and Power Redistribution

From: Political Leadership and Power Redistribution
Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.
Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p

Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Fig. 1 Flow chart of study selection

Fig. 1 Flow chart of study selection
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser
Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.
From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

Similar presentations

Ads by Google